|
1
|
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice.
|
J Clin Invest
|
2008
|
3.11
|
|
2
|
Development of receptor for advanced glycation end products-directed imaging of atherosclerotic plaque in a murine model of spontaneous atherosclerosis.
|
Circ Cardiovasc Imaging
|
2008
|
1.58
|
|
3
|
The RAGE axis in early diabetic retinopathy.
|
Invest Ophthalmol Vis Sci
|
2005
|
1.55
|
|
4
|
RAGE: a novel biological and genetic marker for vascular disease.
|
Clin Sci (Lond)
|
2009
|
1.52
|
|
5
|
Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases.
|
Rheumatology (Oxford)
|
2009
|
1.36
|
|
6
|
Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy.
|
J Am Soc Nephrol
|
2003
|
1.30
|
|
7
|
Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene.
|
FASEB J
|
2009
|
1.23
|
|
8
|
Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?
|
Arterioscler Thromb Vasc Biol
|
2005
|
1.14
|
|
9
|
Percutaneous cell delivery into the heart using hydrogels polymerizing in situ.
|
Cell Transplant
|
2009
|
1.13
|
|
10
|
RAGE ligand upregulation of VEGF secretion in ARPE-19 cells.
|
Invest Ophthalmol Vis Sci
|
2007
|
1.11
|
|
11
|
Alternative splicing of RAGE: roles in biology and disease.
|
Front Biosci (Landmark Ed)
|
2011
|
1.08
|
|
12
|
Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis.
|
Ann N Y Acad Sci
|
2005
|
1.01
|
|
13
|
The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients.
|
Diabetes
|
2003
|
0.96
|
|
14
|
Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signaling.
|
Cancer Res
|
2010
|
0.95
|
|
15
|
Soluble RAGE: a hot new biomarker for the hot joint?
|
Arthritis Res Ther
|
2005
|
0.90
|
|
16
|
The RAGE Gly82Ser polymorphism is not associated with cardiovascular disease in the Framingham offspring study.
|
Atherosclerosis
|
2005
|
0.89
|
|
17
|
RAGE binds C1q and enhances C1q-mediated phagocytosis.
|
Cell Immunol
|
2012
|
0.88
|
|
18
|
Receptor for advanced glycation endproducts mediates pro-atherogenic responses to periodontal infection in vascular endothelial cells.
|
Atherosclerosis
|
2010
|
0.85
|
|
19
|
RAGE and its ligands: a lasting memory in diabetic complications?
|
Diab Vasc Dis Res
|
2004
|
0.84
|
|
20
|
RAGE polymorphisms and the heritability of insulin resistance: the Leeds family study.
|
Diab Vasc Dis Res
|
2005
|
0.82
|
|
21
|
Alternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function.
|
PLoS One
|
2013
|
0.81
|
|
22
|
The ligand/RAGE axis: lighting the fuse and igniting vascular stress.
|
Curr Atheroscler Rep
|
2006
|
0.79
|
|
23
|
Kansuinine A and Kansuinine B from Euphorbia kansui L. inhibit IL-6-induced Stat3 activation.
|
Planta Med
|
2010
|
0.77
|
|
24
|
Inflammatory stress in primary venous and aortic endothelial cells of type 1 diabetic mice.
|
Diab Vasc Dis Res
|
2009
|
0.76
|